On July 1, 2025, Lake Street analyst Thomas Flaten initiated coverage on Aytu BioPharma (AYTU, Financial) with a "Buy" rating. The firm announced a price target of $8.00 USD for the stock. This marks the first coverage from Lake Street on AYTU, providing a positive outlook for potential investors.
Currently trading on NASDAQ, Aytu BioPharma (AYTU, Financial) is set to be closely watched by market participants following Lake Street's coverage initiation. The announcement comes as part of the firm's broader analysis efforts within the biopharmaceutical sector.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for Aytu BioPharma Inc (AYTU, Financial) is $9.00 with a high estimate of $9.00 and a low estimate of $9.00. The average target implies an upside of 320.56% from the current price of $2.14. More detailed estimate data can be found on the Aytu BioPharma Inc (AYTU) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, Aytu BioPharma Inc's (AYTU, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Aytu BioPharma Inc (AYTU, Financial) in one year is $0.86, suggesting a downside of 59.81% from the current price of $2.14. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Aytu BioPharma Inc (AYTU) Summary page.
